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Plasma renin activity (PRA) is an essential analytical tool for screening and diagnosis of secondary forms of
hypertension. Typically, PRA is measured by competitive radioimmunoassay, but there are significant drawbacks
to this technique including non-specificity, long analysis times, narrow calibration range, and the requirement for
radionucleotides. In this paper, we report a method for plasma renin activity determination by immuno-MALDI mass
spectrometry detection. This method overcomes the issues of non-specificity and long analytical times present with
RIA, and does not require the use of radionucleotides. As an initial methodological evaluation, plasma renin activity
results obtained by radioimmunoassay, LC/ESI-MS/MS, and immuno-MALDI on 64 samples from an outpatient
primary aldosteronism screening program have been compared. A strong correlation was found between
immuno-MALDI and radioimmunoassay (R2 = 0.9412, 62/64 within the 95% CI of the Bland-Altman plot), and iMALDI
and LC/ESI-MS/MS (R2 = 0.9471, 62/64 within the 95% CI of the Bland-Altman plot). Technical replicates showed a
4.8% CV, while inter- and intra-day replicates showed CVs of 17.3% and 17.2% respectively. We have developed an
assay capable of measuring PRA without the use of radionucleotides. This immuno-MALDI approach affords the
specificity of MS while avoiding the long analytical run times and technical problems associated with HPLC. With the
use of robotic sample preparation to optimize precision, this assay should be adaptable to clinical environments.
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Hypertension is a world-wide epidemic affecting more
than 1 billion people and causing 7.1 million deaths per
year [1]. The consequences of untreated hypertension
include increased risk of: coronary and peripheral vascu-
lar disease, stroke, congestive heart failure, and chronic
renal impairment. Early identification of treatable and/or
curable forms of hypertension is therefore critical to the
prevention of the associated chronic diseases.
Arterial blood pressure is regulated by the renin-
angiotensin-aldosterone system (RAAS). Dysregulation
of this system leads to the development of certain* Correspondence: christoph@proteincentre.com
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article, unless otherwise stated.hypertensive states that are responsive to surgical, vascu-
lar, or medical intervention–most notably primary aldos-
teronism (PA) and renal arterial stenosis. The RAAS
is regulated by renin, a proteolytic enzyme secreted by
the juxtaglomerular cells of the renal glomerulus in
response to β-1 adrenergic stimulation, decreased arterial
blood pressure, and decreased delivery of NaCl to the
macula densa. Renin cleaves the decapeptide angiotensin-I
(Ang-I) from angiotensinogen, an α-2 globulin constitu-
tively manufactured by the liver. Through the action of
the angiotensin-converting-enzyme (ACE), Ang-I is con-
verted to angiotensin-II (Ang-II), a potent vasoconstrictor.
This leads to a rapid rise in blood pressure and subsequent
upregulation of aldosterone production by the adrenal
glands. Both Ang-II and aldosterone then feedback to de-
crease plasma renin activity (PRA).
The determination of PRA is a critical tool for the
screening and diagnostic process of PA and has a longtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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http://www.clinicalproteomicsjournal.com/content/10/1/20history of diagnostic utility [2,3]. Traditionally, PRA as-
says have been performed using a 1-3 h generation of
Ang-I, which is sometimes extended to 18 h for samples
demonstrating very low activity [3]. Early assays used a
pH of 7.4 [2] which was later decreased to 5.5 - 6.0 to
improve sensitivity [3,4] and angiotensinase inhibition
[5]. The Ang-I generated was protected from proteolytic
degradation either by adding an ACE/angiotensinase in-
hibitor [3] or by antibody capture [6] and the generation
was halted either chemically (11) or by using an ice-bath
[3]. Although various immunoassay techniques for PRA
have been used [7,8], radioimmunoassay (RIA) has been
the mainstay [2].
Recently, screening efforts for PA have increased as phy-
sicians became aware of its high prevalence [9,10]. This
has increased the need for high-throughput methods for
measuring RAAS components. Accordingly, there has
been movement away from traditional PRA assays because
they are not readily amenable to automation. In their
place, sandwich assays measuring plasma renin concen-
tration (PRC) have become commonplace, particularly
since the development of automated chemiluminescent
approaches [11-13].
Although some studies have found PRC to be an ad-
equate substitute for PRA when calculating the aldoster-
one to renin ratio [12,14-17], there are a number of
arguments for retaining PRA as the method of choice.
First, there is a larger body of evidence for PA screening
using PRA, and PRA levels correlate better with plasma
Ang-I and Ang-II. Direct comparisons of the aldoster-
one:PRA versus aldosterone:PRC ratios generally showFigure 1 iMALDI workflow. Stable-isotope labelled internal standard (SIS)
anti-Ang-I-antibody conjugated beads. After immunoprecipitation of endog
MALDI target. To elute the analytes and permit MALDI-MS analysis, CHCA m
are used for quantitation.that the former has higher area-under-the-ROC-curve
[16,18]. Moreover, aldosterone:PRC may suffer from a
higher false-positive rate in women [19].
Enthusiasm for the PRA assay has therefore contin-
ued [20], and MS-based approaches for Ang-I deter-
mination have been of great interest because of their
specificity. Published MS-based methods have used solid-
phase extraction (SPE) and positive ion LC/ESI-MS/
MS [21,22]. Although this approach is radionucleotide-
free, LC/ESI-MS/MS requires considerable expertise
and many clinical laboratories have shied away from
this technique because of its technical demands [23].
In contrast, MALDI-TOF is widely used in clinical
laboratories for the rapid speciation of bacteria and
yeast, because of its speed, ease, robustness, and low
cost [24-26]. Because of this, we have developed a PRA
assay using a MALDI platform (Figure 1). This assay uses
immunocapture coupled to MALDI analysis (iMALDI)
[27-30], is free of radionucleotides, does not require
HPLC, and shows good correlation with existing clinical
RIA and LC/ESI-MS/MS methods.
Results and discussion
This paper describes a 3-way comparison of methods for
determining PRA: the traditional method, using RIA,
which involves radionucleotides; an LC-MS/MS method
involving on-line HPLC separation and electrospray
ionization [31] for quantitation of angiotensin, and an
iMALDI method which does not involve either HPLC
separation or radioactivity, but instead utilizes antibody
capture of angiotensin. In the iMALDI method, the-Ang-I (green) is spiked into plasma and the sample is incubated with
enous (blue) and SIS-Ang-I the beads can be placed directly on a
atrix is applied. The relative abundances of endogenous to SIS-Ang-I
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MALDI analysis of the affinity beads which are placed
on the MALDI target without prior elution of the cap-
tured analyte. The same patient samples were analyzed
by all three methods.PRA determination by the LC/ESI-MS/MS method
LC-MS/MS analysis showed a coefficient of determin-
ation (R2) of 0.9296 for 64 clinical RIA values, with a
slope of 1.68. Sixty-two of the 64 samples were within
the 95% CI of the Bland-Altman plot (Figure 2). These
two methods were used as comparison methods to judge
the correlation of the iMALDI results with those from a
PRA assay at pH 7.4 (for the RIA analysis) and pH 6.0
(for the LC/ESI-MS/MS analysis). The inter-day repro-
ducibility of biological replicates of the LC/ESI-MS/MS
assay was found to be 8.3%, 7.7%, and 9.0% CV at PRA
values of 0.26, 1.34, and 5.63 ng/L/s respectively, as de-
termined by a CLSI EP5-A2-compliant protocol [32].Comparison of PRA determination by iMALDI, RIA, and
LC/ESI-MS/MS
The iMALDI versus RIA values showed an R2 of 0.9412
across 64 clinical samples, with a slope of 2.48. Sixty-
two of the 64 samples were within the 95% CI of the
Bland-Altman plot (Figure 3A). The iMALDI results
were also compared to PRA values determined by LC-
MS/MS, and showed an R2 of 0.9471 with a slope of
1.46. Sixty two of the 64 samples were within the 95%
CI of the Bland-Altman plot (Figure 3B). Inter-day (1
replicate per day for 5 consecutive days)- and intra-day
(5 replicates in 1 day) reproducibility of biological repli-
cates measured by iMALDI were 17.3% CV and 17.2%
CV, respectively, at a PRA value of 0.38 ng/L/s, with
technical replicates averaging 4.8% CV.Figure 2 Correlation of RIA with LC/ESI-MS/MS. PRA was determined b
Passing and Bablok regression as well as a Bland Altman difference plot. ShThe iMALDI assay for PRA using a 1-h incubation
and a 1-h antibody capture which shows a strong correl-
ation with RIA and LC-MS/MS methods (n = 64, R2 =
0.9412 and R2 = 0.9471 with RIA and LC-MS/MS, re-
spectively). This iMALDI method improves on many as-
pects of the RIA procedure – mainly the exclusion of
radionucleotides and inaccuracies associated with anti-
body cross-reactivity. This method employs antigen-
concentration by immunocapture, and direct elution on
the MALDI target (Figure 1), which reduces the risk of
non-specific binding to plastics [33]. The specificity pro-
vided by the mass spectrometer allows the accurate de-
termination of MWs of all antibody-captured analytes,
ensuring that antibody cross-reactivity does not result in
analytical interferences. This specificity is important,
because some between-method variability is believed to
result from biologically-inactive, yet immunologically
cross-reactive components present in patient plasma
[34]. In iMALDI, if additional components are captured
by the antibody, they are detected as different compo-
nents and can be accounted for (Figure 4).
In MALDI-MS, a standard curve can be created by
capture of synthetic natural and SIS Ang-I peptide from
1xPBS/0.03% CHAPS buffer. The same standard curve is
used for both the generated (37°C) and blank (4°C) sam-
ples to quantitate Ang-I and to calculate PRA. The use
of SIS peptides as internal standard allows MALDI, and
our iMALDI approach, to be quantitative [35].
PRA values determined by iMALDI were compared to
those of RIA and LC/ESI-MS/MS. Figure 3A shows the
regression relationship of iMALDI to RIA for PRA,
which has a slope of 2.48. The deviation of the slope
from unity can be partially explained by the substantial
increase in PRA seen for incubations performed at lower
pH [36]. Historically, PRA assays were performed at
physiological pH = 7.4, but this was later altered to pH =y RIA and LC/ESI-MS/MS for 64 patients. The correlation is shown by
aded regions represent a 95% confidence interval.
Figure 3 Correlation of iMALDI with RIA and LC/MS/MS. A) Difference plot comparisons for RIA and iMALDI. B) Difference plot comparison
for LC/ESI-MS/MS and iMALDI.
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tensinase inhibition [3]. When identical samples are run
at pH = 7.4 and pH = 6.0, the PRA for samples run at
pH = 6.0 show roughly twice the activity of the samples
run at pH = 7.4 [3]. The RIA assay utilized pH = 7.4,
while the iMALDI assay used pH = 6.0. Additionally,
there are slight differences observed in PRA values when
plasma samples are diluted to different extents [36].
Figure 3B shows the comparison of iMALDI with LC/
ESI-MS/MS, which has a slope of 1.46. Both methods
were run at pH = 6.0, but the LC/ESI-MS/MS method
has an Ang-I generation time of 3 h, compared to a 1-h
generation for the iMALDI assay. Because Ang-I gener-
ation by renin is substrate dependant, different gener-
ation times will result in different numerical PRA results
with shorter incubations resulting in higher values [37].
Conclusions
We have developed an iMALDI assay for PRA that elim-
inates the use of radionucleotides and reduces the dele-
terious effects of antibody cross-reactivity. The iMALDI
results using this assay show a strong correlation with
existing PRA methods currently used in routine clinicalcare, while requiring only a 1-h Ang-I generation period
and a 1-h antigen capture step. With automation of
sample preparation, we expect to see even further im-
provements in the throughput and precision of the
assay. MALDI instruments are currently being installed
in clinical laboratories throughout the world for the
identification of bacteria [38]. Because iMALDI can be
performed on these same instruments, the assay pre-
sented here has potential for translation to the clinic.
Experimental procedures
Plasma samples
Plasma samples were obtained from a cohort of 64 sub-
jects from the outpatient PRA-screening program of
St. Paul’s Hospital (SPH) Laboratory, selected to span
the analytical range of the RIA assay (0.05-2.00 ng/L/s
using pH = 7.4 incubation) [6]. Samples were collected
into pre-chilled EDTA tubes, centrifuged at 4°C, and fro-
zen at −20°C for at most 10 days. Specimens were
thawed for 5 min in a room temperature (RT) water
bath and immersed in ice-water prior to RIA [6] and
LC/ESI-MS/MS analysis, using a variation of our previous
method [31]. Samples were then refrozen and maintained
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(UVic) - Genome BC Proteomics Centre. Because freeze-
thaw cycles can cause elevation of PRA due to prorenin
cryoactivation, samples spent minimal times at refrigeration
temperatures where cryoactivation is greatest [3].
This study was approved by the research ethics board
of the University of British Columbia and SPH.
Chemicals and reagents
RIA and LC/ESI-MS/MS
RIA analysis used a rabbit polyclonal anti-angiotensin
antiserum prepared according to a published protocol
[39]. Purified Ang-I was purchased from Proteochem.
BSA and glacial acetic acid were purchased from EMD
Millipore. Radiolabeled Ang-I (Human, [125I]Tyr4-, 10 μCi
(370 kBq), 125I-Ang-I) tracer was purchased from Perkin
Elmer. Tris, EDTA, formic acid (FA) and PMSF were pur-
chased from Sigma Aldrich. Dextran was purchased from
MP Biomedical, and activated charcoal and methanol were
purchased from Fisher Scientific. Stable-isotope labelled
internal standard (SIS) Ang-I (DR*VYIHPFHL, +10 Da)
was prepared by the UVic - Genome BC ProteomicsFigure 4 The determination of PRA by iMALDI. A) A standard curve is c
spectra showing capture of natural and SIS Ang-I in a 4°C sample. C) MALDCentre. Briefly, C-terminal [13C]/[15N] labeled tryptic pep-
tides were synthesized using an N-(9-fluorenyl)methoxy-
carbonyl) procedure on a Prelude peptide synthesizer
(Protein Technologies). Peptides were purified by HPLC,
purity was confirmed by MALDI-TOF-MS, characteriza-
tion was done by capillary zone electrophoresis at the
University of British Columbia (Vancouver, Canada), and
by amino acid analysis at the Hospital for Sick Children
(Toronto, Canada) [40].iMALDI reagents
Goat polyclonal anti-angiotensin antibody (pAb) (SC-7419)
was purchased from Santa Cruz Biotechnology. Magnetic
protein G Dynabeads were purchased from Invitrogen.
Synthetic peptides (natural and SIS) were synthesized
in house [40]. TFA was purchased from Fisher Scientific.
PBS, CHAPS, EDTA, maleic acid, neomycin trisulphate
salt hydrate, PMSF, ammonium bicarbonate, α-cyano-
4-hydroxycinnamic acid (CHCA), ammonium citrate
dibasic, LC/MS-grade H2O, and LC/MS-Grade ACN were
purchased from Sigma Aldrich.reated from antibody captures of natural and SIS peptides. B) MALDI
I spectra showing capture of natural and SIS Ang-I in a 37°C sample.
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Preparation of reference standards
Reference standards were prepared by dissolving purified
Ang-I in a buffer containing 1% BSA in 0.1 M Tris, to
make a stock concentration of 5000 μg/mL Ang-I. The
stock solution was spiked and then serially diluted to
make a calibration curve at 10, 5, 2.5, 1.25, 0.625, 0.313,
and 0.156 ng/mL in a 1% BSA in 0.1 M Tris buffer.
Generation of angiotensin I
Frozen plasma samples were thawed for 5 minutes in a
RT water bath followed immediately by immersion in an
ice-water bath, where they remained, except for the 37°C
generation step. Patient samples, reference standards,
and controls were aliquoted in duplicate for the 37°C in-
cubation and the blank (ice-water bath) incubation. Ten
μL of rabbit anti-angiotensin in a 1 M Tris/0.2 M EDTA
buffer at pH = 7.4 were added to each conical polystyr-
ene tube (Evergreen Scientific), followed by 50 μL of
standards and unknowns. The 37°C-incubation tubes
were placed in a 37°C water bath for exactly 1 h; the
blank tubes were kept in the ice bath. At the end of the
incubation period, the 37°C samples were immediately
returned to the ice bath.
RIA analysis
The 125I-Ang-I tracer was diluted in 0.1 M Tris to yield
18,000-22,000 CPM/mL, and 1 mL was added to each
tube. Fifty μL of plasma with undetectable PRA was
added to all standard tubes to act as a suitable matrix.
Tubes were vortexed and incubated at 4°C for 48–72 h
to allow the competitive binding of the 125I-Ang-I to the
anti-angiotensin antibody.
At the end of incubation, 500 μL of cold dextran-
coated charcoal in 0.1 M Tris was added to each sample,
mixed, and centrifuged. The supernatant was decanted
into round-bottom polystyrene tubes (Simport). The su-
pernatants were counted on a Wallac 1260 MULTI-
GAMMA II gamma counter (Perkin Elmer). Data
reduction was performed using StatLIA Enterprise 3.2
(Brendan Technologies). PRA was calculated as ng/L/s
using blank subtraction (Equation 1).




Preparation of reference standards
Reference standards were prepared in the same manner
as the RIA analysis. Concentrations of 100, 30, 9.0, 2.7,
1.35, 0.675, and 0.3375 ng/mL were prepared in a 1%
BSA in 0.1 M Tris buffer.Generation of angiotensin I
Plasma samples were received for LC/ESI-MS/MS ana-
lysis in an ice bath, immediately after being aliquoted for
RIA analysis. Two hundred and fifty μL of reference
standards and plasma samples were added in duplicate
to two square polypropylene 2-mL 96 well plates (Corn-
ing Inc.), for the 37°C and blank determinations, respect-
ively. The 37°C generation plate contained 50 μL of the
generation buffer (1 M Tris, 0.2 M EDTA, and 1 mM
PMSF at pH 5.5) resulting in a plasma pH of 6.0. The
37°C generation plate was mixed briefly, and placed in a
37°C water bath for exactly 3 h. The blank plate was ex-
tracted by SPE immediately after samples were ali-
quoted. The blank-subtraction plate was not subjected
to a 3-h incubation on ice.Extraction of angiotensin I
Three hundred μL of Ang-I-SIS internal standard, at
10 ng/mL in 10% FA, was aliquoted to each sample, and
mixed briefly. A Strata-X 33 μ polymeric reversed phase
60 mg 96 well plate (Phenomenex) was conditioned with
1 mL of methanol followed by 1 mL of 5% FA with vac-
uum applied at 200 mbar for 1 min for each condition
step. The entire sample (550 μL for blank samples and
600 μL for 37°C samples) was loaded onto the plate and
flowed through using vacuum applied at 200 mbar for
1 min. The plate was washed with 5% FA followed by
20% methanol with vacuum applied at 200 mbar for
1 min for each wash step and dried under 200 mbar of
vacuum for 10 min. Ang-I was eluted from the plate
with 250 μL of methanol and collected in a 2-mL poly-
propylene round-bottom 96 well plate (NUNC/Thermo
Fisher) with 200 mbar of vacuum applied for 2 min.LC/ESI-MS/MS analysis
LC/ESI-MS/MS analysis was performed on a UFLC 20 AC
(Shimadzu Corporation) with an AB SCIEX API5000
triple-quadrupole (Applied Biosystems). Twenty microliters
of sample extracts were injected onto a 50 mm x 2 mm Ju-
piter 4 μ Proteo 90A Analytical Column (Phenomenex).
Mobile phases A and B were 0.2% FA in water, and 0.2%
FA in methanol, respectively. Using a 0.5 mL/min flow rate,
Ang-I was eluted at 95% B after 0.5 min of column
conditioning at 10% B and a gradient to 95% B in 1 min.
The system was returned to starting conditions in 0.1 min
and re-equilibrated at 10% B for 2.4 min. The total
cycle time was 6 min per sample. Triply-charged ions
433.2→647.5 (quantifier) and 433.2→619.3 (qualifier) were
monitored for Ang-I and 436.6→657.5 for the SIS-Ang-I
internal standard. Calibration curves were fit with 1/x2
linear regression. PRA was calculated in ng/L/s using
Equation 1.
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Washing of protein G dynabeads
Protein G Dynabeads were used at a ratio of 5 μL of
bead slurry (30 mg/mL) per 1 μg of pAb. Beads were
washed 7 times with 1 mL of 25% ACN/1xPBS/0.03%
CHAPS, and 3 times with 1xPBS/0.03% CHAPS solution
in a 1.5 mL Maxymum Recovery tube (Axygen Scien-
tific). Beads were pelleted with a Dynamag-2 (Invitro-
gen), allowing 20 s to pellet the beads before removing
the supernatant.
Conjugation of protein G dynabeads and pAb
Antibody was added to Protein G Dynabeads based on
experimental need (1 plate used roughly 23 μg of pAb)
at a ratio of 1 μg of pAb to 5 μL of washed beads. A so-
lution of 1xPBS/0.03% CHAPS was added to give a final
volume of 7 μL of liquid per 1 μg of pAb. The sample
was quickly spun to collect beads at the bottom of the
tube and then lightly vortexed to resuspend them. Beads
were placed on a Labquake rotor (Fisher Scientific) for
1 h at RT with end-over-end rotation. Following conju-
gation, beads were pelleted and washed 5 times with
1 mL of 1×PBS/0.03% CHAPS. Once washed, beads
were resuspended in 1×PBS/0.03% CHAPS to a pAb
concentration of 0.01 μg/μL. Twenty μL of bead solution
was transferred to each well of a 96-well skirted PCR
plate, which results in 0.2 μg of pAb per capture well.
Generation of angiotensin I
Plasma samples were thawed in a RT water bath for
5 min and then placed on ice. Before use, plasma was
vortexed and a 200 μL aliquot was added to a 1.5-mL
Maxymum Recovery tube, to give a final concentration
of 5 mM EDTA, 25 mM maleic acid, 275 μM neomycin
trisulphate, and 1 mM PMSF. The final sample pH was
6. The total volume of all inhibitors added was 12.23 μL,
resulting in a 6% dilution. Samples were vortexed and
split into two tubes containing 100 μL each, representing
the blank and generated sample. The blank sample was
placed on ice, and the generated sample was placed
in a 37°C thermoshake rotor (Eppendorf ), shaking at
1000 rpm for exactly 1 h.
Antigen capture
Beads were pelleted in the 96 well PCR plate (Axygen)
by placing it on a Dynal MPC-96S plate magnet and the
supernatant was removed. Tubes were continually vor-
texed during Ang-I generation, and were then placed on
ice. Triplicate analyses of patient blank and generated
samples were added to the PCR plate (6 captures per pa-
tient). This was repeated for each patient sample, with a
total of 13 patients analyzed per plate (78 wells). Tripli-
cate six-point calibration curves at concentrations of
14.8, 7.4, 3.7, 1.9, 0.9, and 0 ng/mL natural Ang-I wereprepared in 35 μL of 1×PBS/0.03% CHAPS. Both refer-
ence standards and patient samples were spiked with SIS
Ang-I internal standard to a concentration of 4.6 ng/mL.
After addition of the standards, samples were mixed by
pipetting with an 8-channel pipette (Fisher Scientific).
The PCR plate was sealed with an Axymat (Axygen),
taped to a Labquake rotor, and incubated at 4°C for 1 h
with end-over-end rotation.Bead washing and MALDI spotting
Following 1 h of antibody capture, the plate was re-
moved and placed on the PCR plate magnet. Using a
multichannel pipette, samples were washed column by
column, starting with column 1. The capture solution
(plasma and standards) was removed from the pelleted
beads. The PCR plate was removed from the magnet
and 100 μL of 15% ACN/25 mM ammonium bicarbon-
ate was used to resuspend the beads. The PCR plate was
placed back on the magnet and the beads were allowed
to pellet for 20 s. This was repeated an additional 2
times for a total of 3 washes. After the final wash, all
buffer was removed and the plate was removed from the
magnet. Beads were resuspended in 3 μL of 15%ACN/
25 mM ammonium bicarbonate, and the entire bead so-
lution was spotted on a MALDI target (part number:
4352802, AB SCIEX). The procedure was performed for
each column separately to ensure that the time from
first wash to spotting on the MALDI target was consist-
ent across all samples. After all wells had been spotted,
the plate was left at RT until all spots were dry and uni-
form in appearance. Two μL of MALDI matrix solution
(containing 3 mg/mL CHCA, 1.8 mg/mL ammonium
citrate, 70% ACN, and 0.1% TFA) was overspotted onto
each bead spot to elute the peptide and prepare the spot
for MALDI analysis.MALDI analysis
Samples were analyzed on an AB SCIEX 4800 MALDI
TOF-TOF using Reflector Positive mode, from m/z 800
to 4000. Samples were analyzed in batch mode, after
checking before acquisition to ensure that the laser set-
ting produced sufficient intensities for both blank and
generated sample. A total of 1250 laser shots were ac-
quired for each spot (10 sub-spectra with 125 shots
per sub-spectrum) using a fixed laser intensity. Repre-
sentative spectra from a 4°C and 37°C capture are
shown in Figure 4. Figure 4 also shows a peak at m/z
1295.68 – 1 Da lower than the Natural Ang – which
was associated with the antibody. The blank subtrac-
tion method for PRA determination removes any
potential interference from the 13C peak of this com-
ponent (see Additional file 1).
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Data was analyzed using AB SCIEX’s Data Explorer soft-
ware. Peak heights were recorded after performing a
baseline correction. Two peak heights were recorded –
those of Natural Ang-I (m/z 1296.68) and SIS Ang-I
(m/z 1306.68), and the relative response (RR) was re-
ported as the Nat:SIS ratio. These RR values were com-
pared to the calibration curve. PRA was calculated in
ng/L/s by the blank subtraction method (Equation 1).
Regressions were performed by the method of Passing
and Bablok using cp-R, a graphical user interface to the
R statistical programming language [41].
Additional file
Additional file 1: Supplementary information.
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